Free Trial
NASDAQ:UPC

Universe Pharmaceuticals Q4 2025 Earnings Results & Report

Universe Pharmaceuticals logo
$4.15 -0.03 (-0.72%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$4.21 +0.06 (+1.47%)
As of 10/9/2026 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Universe Pharmaceuticals reported Q4 2025 earnings on January 29, 2026. The company reported EPS of $0.69, while revenue was $8.92 billion.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes

Universe Pharmaceuticals EPS Results

Actual EPS
$0.69
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Universe Pharmaceuticals Revenue Results

Actual Revenue
$8.92 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Universe Pharmaceuticals Q4 2025 Earnings FAQ

Universe Pharmaceuticals (NASDAQ:UPC) reported earnings of $0.69 per share for Q4 2025. The report was announced on Thursday, January 29, 2026.

Universe Pharmaceuticals reported revenue of $8.92 billion for Q4 2025.

Universe Pharmaceuticals Earnings Headlines

First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
See More Universe Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Universe Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Universe Pharmaceuticals and other key companies, straight to your email.

About Universe Pharmaceuticals

Universe Pharmaceuticals (NASDAQ:UPC). (NASDAQ: UPC) is a China-based pharmaceutical company engaged in the development, manufacture and sale of traditional Chinese medicine (TCM) products and other healthcare offerings. The company serves consumers primarily through pharmaceutical distributors, retail pharmacies and other sales channels in China.

Universe Pharmaceuticals’ product portfolio includes over-the-counter and prescription pharmaceutical products, as well as healthcare and nutritional products. Its offerings are derived in part from traditional Chinese medicine formulations and are intended to address a range of consumer health needs. The company also provides related product distribution and marketing services.

Founded in 1998, Universe Pharmaceuticals is headquartered in Xi’an, Shaanxi Province, China. Its operations and primary market are concentrated in mainland China. The company completed its initial public offering on the Nasdaq Capital Market in 2021.

View Universe Pharmaceuticals Profile